Californian biotech company Capricor Therapeutics (Nasdaq: CAPR) was trading 6% higher after 90 minutes of trading on Friday.
Markets were reacting to positive final data from the HOPE-2 trial using CAP-1002 to treat patients in advanced stages of Duchenne muscular dystrophy (DMD).
The trial met its primary efficacy endpoint of mid-level performance of upper limb, as well as various skeletal and cardiac endpoints, suggesting clinically relevant slowing of disease progression.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze